Canaccord Genuity analyst Mark Massaro maintained a Buy rating on Heska Corp (HSKA) on June 26 and set a price target of $95. The company’s shares closed on Friday at $85.17.
According to TipRanks.com, Massaro is a top 100 analyst with an average return of 21.3% and a 65.0% success rate. Massaro covers the Healthcare sector, focusing on stocks such as HTG Molecular Diagnostics, Meridian Bioscience Inc, and Quanterix Corporation.
Heska Corp has an analyst consensus of Moderate Buy, with a price target consensus of $95.
See today’s analyst top recommended stocks >>
Based on Heska Corp’s latest earnings release for the quarter ending March 31, the company reported a quarterly net profit of $814K. In comparison, last year the company had a net profit of $2.16 million.
Based on the recent corporate insider activity of 45 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of HSKA in relation to earlier this year. Most recently, in May 2019, Nancy Wisnewski, the EVP, Diag. Ops & Prod. Dev. of HSKA bought 7,000 shares for a total of $32,000.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Heska Corp. engages in the provision of veterinary and animal health diagnostic, and specialty products. It operates through two segments: Core Companion Animal Health and Other Vaccines & Pharmaceuticals.
